{"id":"progesterone-effervescent-vaginal-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaginal irritation or discharge"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Progesterone acts as a ligand for intracellular progesterone receptors (PR-A and PR-B), modulating gene transcription to promote endometrial secretion, reduce uterine contractility, and support early pregnancy maintenance. The effervescent vaginal tablet formulation delivers progesterone directly to the reproductive tract, providing local and systemic hormone replacement or supplementation during the luteal phase or early pregnancy.","oneSentence":"Progesterone is a naturally occurring steroid hormone that binds to progesterone receptors to support luteal phase function and maintain pregnancy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:24.804Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Luteal phase support in assisted reproductive technology (ART)"},{"name":"Early pregnancy maintenance / luteal phase deficiency"}]},"trialDetails":[{"nctId":"NCT05555121","phase":"PHASE2","title":"Rescue Progesterone Supplementation During Frozen Embryo Transfer","status":"SUSPENDED","sponsor":"Clinique Ovo","startDate":"2022-12-01","conditions":"Fertility Issues, Embryo Implantation, Frozen Embryo Transfer","enrollment":150},{"nctId":"NCT05997563","phase":"PHASE4","title":"Adjunctive Vaginal Progesterone in Management of Preterm Labor","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2023-08-16","conditions":"Preterm Labor","enrollment":48},{"nctId":"NCT01941875","phase":"PHASE3","title":"Luteal Phase Progesterone in IUI and Gonadotropin Cycles","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2014-07","conditions":"Infertility","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Endometrin 100 mg twice daily"],"phase":"phase_3","status":"active","brandName":"Progesterone Effervescent Vaginal Tablets","genericName":"Progesterone Effervescent Vaginal Tablets","companyName":"University of Alberta","companyId":"university-of-alberta","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Progesterone Effervescent Vaginal Tablets are used to treat fertility issues, including embryo implantation and frozen embryo transfer, as well as preterm labor. They work by supplementing progesterone, a hormone involved in the menstrual cycle and pregnancy, as indicated by their use in ClinicalTrials.gov for various conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}